• Axsome posted 2Q 2026 net product revenue of $218.4 million, up 46% year over year.
• Net loss widened to $51.3 million, or $(0.99) per share.
• AUVELITY net product sales rose 51% to $180.3 million; SUNOSI net product revenue increased 20% to $35.8 million.
• SG&A expenses climbed to $208.1 million from $130.3 million, driven by AUVELITY commercialization and the Alzheimer’s agitation launch.
• AUVELITY launched for Alzheimer’s agitation in June; FDA accepted the AXS-12 NDA for narcolepsy cataplexy with a May 1, 2027 PDUFA date.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Axsome Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-341206), on August 10, 2026, and is solely responsible for the information contained therein.